{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:24Z","timestamp":1791646464187,"version":"4.3.4"},"reference-count":370,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["BNW-1-157\/N\/4\/K"],"award-info":[{"award-number":["BNW-1-157\/N\/4\/K"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background: Portal hypertension is a major complication of chronic liver diseases, leading to serious issues such as esophageal variceal bleeding. The increase in portal vein pressure is driven by both an organic component and a functional component, including tonic contraction of hepatic stellate cells. These processes result in a pathological rise in intrahepatic vascular resistance, stemming from partial impairment of hepatic microcirculation, which is further exacerbated by abnormalities in extrahepatic vessels, including increased portal blood flow. Objectives: This review aims to provide a comprehensive overview of the evolving pharmacological therapies for portal hypertension, with consideration and discussion of pathophysiological mechanisms, clinical complications, and pharmacogenetic considerations, highlighting potential directions for future research. Methods: A review of recent literature was performed to evaluate current knowledge and potential therapeutic strategies in portal hypertension. Results: For over 35 years, non-selective beta-blockers have been the cornerstone therapy for portal hypertension by reducing portal vein inflow as an extrahepatic target, effectively preventing decompensation and variceal hemorrhages. However, since not all patients exhibit an adequate response to non-selective beta-blockers (NSBBs), and some may not tolerate NSBBs, alternative or adjunctive therapies that enhance the effects of NSBBs on portal pressure are being investigated in preclinical and early clinical studies. Conclusions: A better understanding of pharmacogenetic factors and pathophysiological mechanisms could lead to more individualized and effective treatments for portal hypertension. These insights highlight potential directions for future research.<\/jats:p>","DOI":"10.3390\/metabo15020072","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:01:13Z","timestamp":1737622873000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8378-435X","authenticated-orcid":false,"given":"Micha\u0142","family":"Porada","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-5516","authenticated-orcid":false,"given":"\u0141ukasz","family":"Bu\u0142dak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.001","article-title":"The Role of Different EASL-Papers: Clinical Practice Guidelines vs. Position Papers vs. Conference Summaries","volume":"53","author":"Wedemeyer","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1746.2007.05002.x","article-title":"Guidelines for the Assessment and Management of Non-Alcoholic Fatty Liver Disease in the Asia-Pacific Region: Executive Summary","volume":"22","author":"Farrell","year":"2007","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0002-9343(70)80135-8","article-title":"Hepatic Fibrosis Correlation of Biochemical and Morphologic Investigations","volume":"49","author":"Popper","year":"1970","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","article-title":"Hepatic Endothelial Dysfunction and Abnormal Angiogenesis: New Targets in the Treatment of Portal Hypertension","volume":"53","author":"Bosch","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of Portal Hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated Cirrhosis: Natural History and Prognostic Factors","volume":"7","author":"Quintero","year":"1987","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.12688\/f1000research.18807.1","article-title":"Management of Acute Variceal Hemorrhage","volume":"8","author":"Zanetto","year":"2019","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990\u20132013: A Systematic Analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Naghavi","year":"2015","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, Regional, and National Age-Sex Specific Mortality for 264 Causes of Death, 1980\u20132016: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tapper, E.B., and Parikh, N.D. (2018). Mortality Due to Cirrhosis and Liver Cancer in the United States, 1999\u20132016: Observational Study. BMJ Online, 362.","DOI":"10.1136\/bmj.k2817"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0973-6883(11)60128-X","article-title":"Noncirrhotic Portal Hypertension","volume":"1","author":"Rajekar","year":"2011","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.disamonth.2016.08.001","article-title":"Portal Hypertension: Etiology, Evaluation, and Management","volume":"62","author":"Tetangco","year":"2016","journal-title":"Dis. Mon."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12072-021-10135-4","article-title":"Regression of Portal Hypertension: Underlying Mechanisms and Therapeutic Strategies","volume":"15","author":"Selicean","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural History and Prognostic Indicators of Survival in Cirrhosis: A Systematic Review of 118 Studies","volume":"44","author":"Pagliaro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing Risks and Prognostic Stages of Cirrhosis: A 25-Year Inception Cohort Study of 494 Patients","volume":"39","author":"Pasta","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0000000000000207","article-title":"Serum Albumin Can Identify Patients with Compensated Cirrhosis with a Good Prognosis","volume":"49","author":"Ripoll","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the Understanding of the Pathophysiological Basis of Portal Hypertension: How Changes in Paradigm Are Leading to Successful New Treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension HHS Public Access","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver Fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-2-4","article-title":"Hepatic Wound Repair","volume":"2","author":"Parola","year":"2009","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_21","first-page":"719","article-title":"Presence of Modified Fibroblasts in Granulation Tissue and Their Possible Role in Wound Contraction","volume":"35","author":"Gabbiani","year":"1971","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1083\/jcb.127.6.2037","article-title":"Expression of Variant Fibronectins in Wound Healing: Cellular Source and Biological Activity of the EIIIA Segment in Rat Hepatic Fibrogenesis","volume":"127","author":"Jarnagin","year":"1994","journal-title":"J. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbalip.2008.11.001","article-title":"Hepatic Stellate Cell Lipid Droplets: A Specialized Lipid Droplet for Retinoid Storage","volume":"1791","author":"Blaner","year":"2009","journal-title":"Biochim. Biophys. Acta-Mol. Cell Biol. Lipids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic Stellate Cells in Liver Development, Regeneration, and Cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.50.4.571","article-title":"Hepatic Stellate Cells: Role in Microcirculation and Pathophysiology of Portal Hypertension","volume":"50","author":"Reynaert","year":"2002","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of Cirrhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-up Study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.v7.i1.1","article-title":"Advances in Gene Therapy of Liver Cirrhosis: A Review","volume":"7","author":"Dai","year":"2001","journal-title":"World J. Gastroenterol."},{"key":"ref_29","first-page":"85","article-title":"The Etiology, Diagnosis and Prevention of Liver Cirrhosis","volume":"110","author":"Wiegand","year":"2013","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of Liver Fibrosis: A Translational Success Story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: An Overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: The Impact of Multiple Pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD Development and Therapeutic Strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and Epigenetics of NAFLD and NASH: Clinical Impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population","volume":"71","author":"Ruhl","year":"2020","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD Genetics: From New Variants to the Clinic","volume":"72","author":"Valenti","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic Pipeline in Nonalcoholic Steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The Biology of VEGF and Its Receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-06-3567","article-title":"Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth","volume":"67","author":"Laakkonen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","article-title":"Blocking VEGFR-3 Suppresses Angiogenic Sprouting and Vascular Network Formation","volume":"454","author":"Tammela","year":"2008","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2006.02.018","article-title":"The VEGF-C\/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells","volume":"9","author":"Su","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/1078-0432.CCR-08-0818","article-title":"Vascular Endothelial Growth Factor C Stimulates Progression of Human Gastric Cancer via Both Autocrine and Paracrine Mechanisms","volume":"14","author":"Kodama","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1440-1746.2005.04217.x","article-title":"Expression of Vascular Endothelial Growth factor-C in Human Hepatocellular Carcinoma","volume":"21","author":"Yamaguchi","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcla.21672","article-title":"Role of VEGF-C Gene Polymorphisms in Susceptibility to Hepatocellular Carcinoma and Its Pathological Development: VEGF-C Gene Polymorphisms in HCC","volume":"28","author":"Hsieh","year":"2014","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Pories, S. (2010). Evidence for the Role of Bevacizumab in the Treatment of Advanced Metastatic Breast Cancer: A Review. Breast Cancer Targets Ther., 37.","DOI":"10.2147\/BCTT.S6511"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cao, L.N., Cheng, S.L., and Liu, W. (2016). IL10 Rs1800896 Polymorphism Is Associated with Liver Cirrhosis and Chronic Hepatitis B. Genet. Mol. Res., 15.","DOI":"10.4238\/gmr.15017256"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1478-3231.2007.01518.x","article-title":"Influence of IL-10RA and IL-22 Polymorphisms on Outcome of Hepatitis C Virus Infection","volume":"27","author":"Hennig","year":"2007","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zheng, M., Fang, W., Yu, M., Ding, R., Zeng, H., Huang, Y., Mi, Y., and Duan, C. (2021). IL-6 and IL-10 Gene Polymorphisms and Cirrhosis of Liver Risk from a Comprehensive Analysis. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00906-3"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00365513.2017.1420217","article-title":"Serum Level of Interleukin-6 (IL-6) and N-Terminal Propeptide of Procollagen Type I (PINP) in Patients with Liver Diseases","volume":"78","author":"Wrona","year":"2018","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3892\/ijmm.2016.2595","article-title":"Interleukin-6 and Rs1800796 Locus Single Nucleotide Polymorphisms in Response to Hypoxia\/Reoxygenation in Hepatocytes","volume":"38","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/gene.2015.40","article-title":"IL6 Gene Allele-Specific C\/EBP\u03b1-Binding Activity Affects the Development of HBV Infection through Modulation of Th17\/Treg Balance","volume":"16","author":"Zhang","year":"2015","journal-title":"Genes Immun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.humimm.2018.12.009","article-title":"Interleukin-6 Promotor Gene Polymorphisms and Susceptibility to Chronic Hepatitis B Virus in Egyptians","volume":"80","author":"Talaat","year":"2019","journal-title":"Hum. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e18408","DOI":"10.1097\/MD.0000000000018408","article-title":"Interleukin-6 Gene Polymorphisms and Susceptibility to Liver Diseases: A Meta-Analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.alcohol.2008.04.008","article-title":"Serum TNF-\u03b1 Levels in Relation to Alcohol Consumption and Common TNF Gene Polymorphisms","volume":"42","author":"Campos","year":"2008","journal-title":"Alcohol"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/2011\/805275","article-title":"Associations of \u2212308 G\/A Polymorphism of Tumor Necrosis Factor (TNF)\u2014\u03b1 Gene and Serum TNF- \u03b1 Levels with Measures of Obesity, Intra-Abdominal and Subcutaneous Abdominal Fat, Subclinical Inflammation and Insulin Resistance in Asian Indians in North India","volume":"31","author":"Vikram","year":"2011","journal-title":"Dis. Markers"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cyto.2011.07.002","article-title":"TNF-Alpha and IL-8: Serum Levels and Gene Polymorphisms (\u2212308G>A and \u2212251A>T) Are Associated with Classical Biomarkers and Medical History in Children with Sickle Cell Anemia","volume":"56","author":"Cajado","year":"2011","journal-title":"Cytokine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2005.09.022","article-title":"Association of TNF-\u03b1 Serum Levels and TNFA Promoter Polymorphisms with Risk of Myocardial Infarction","volume":"187","author":"Bennet","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clinre.2015.10.007","article-title":"Associations between the Tumor Necrosis Factor-\u03b1 Gene and Interleukin-10 Gene Polymorphisms and Risk of Alcoholic Liver Disease: A Meta-Analysis","volume":"40","author":"Zhao","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/MEG.0000000000000878","article-title":"Influence of Genetic Variations in the SOD1 Gene on the Development of Ascites and Spontaneous Bacterial Peritonitis in Decompensated Liver Cirrhosis","volume":"29","author":"Schwab","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.dld.2018.08.005","article-title":"ACE I Allele Is Associated with More Severe Portal Hypertension in Patients with Liver Cirrhosis: A Pilot Study","volume":"51","author":"Annicchiarico","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-Analysis of the Influence of I148M Variant of Patatin-like Phospholipase Domain Containing 3 Gene (PNPLA3) on the Susceptibility and Histological Severity of Nonalcoholic Fatty Liver Disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Semmler, G., Balcar, L., Oberkofler, H., Zandanell, S., Strasser, M., Niederseer, D., Feldman, A., Stickel, F., Strnad, P., and Datz, C. (2021). PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030165"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0168-8278(00)80119-1","article-title":"Chronic Liver Disease in Heterozygous A1-Antitrypsin Deficiency PiZ","volume":"33","author":"Fischer","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/jgh.14700","article-title":"Impact of Farnesoid X Receptor Single Nucleotide Polymorphisms on Hepatic Decompensation and Mortality in Cirrhotic Patients with Portal Hypertension","volume":"34","author":"Semmler","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.12140","article-title":"Review Article: Liver Transplantation for the Pulmonary Disorders of Portal Hypertension","volume":"37","author":"Houlihan","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12328-019-00956-0","article-title":"Vascular Syndromes in Liver Cirrhosis","volume":"12","author":"Shenoda","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/gut.52.9.1355","article-title":"Portopulmonary Hypertension in Decompensated Cirrhosis with Refractory Ascites","volume":"52","author":"Benjaminov","year":"2003","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary Hypertension Complicating Portal Hypertension: Prevalence and Relation to Splanchnic Hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/jhep.2003.50060","article-title":"Diagnosis of Portopulmonary Hypertension in Candidates for Liver Transplantation: A Prospective Study","volume":"37","author":"Colle","year":"2003","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary Hypertension: A Report from the US-Based REVEAL Registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000001229","article-title":"International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension","volume":"100","author":"Krowka","year":"2016","journal-title":"Transplantation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review","volume":"73","author":"Sanz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"D22","DOI":"10.1016\/j.jacc.2013.10.027","article-title":"Right Heart Adaptation to Pulmonary Arterial Hypertension","volume":"62","author":"Haddad","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjcard.2017.05.053","article-title":"Load Adaptability in Patients With Pulmonary Arterial Hypertension","volume":"120","author":"Amsallem","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jcmg.2011.11.020","article-title":"RV Dysfunction In Pulmonary Hypertension Is Independently Related To Pulmonary Artery Stiffness","volume":"5","author":"Stevens","year":"2012","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1164\/rccm.201806-1160ST","article-title":"Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward an Official American Thoracic Society Research Statement","volume":"198","author":"Lahm","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCIMAGING.113.000640","article-title":"Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension","volume":"6","author":"Fine","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.112.000008","article-title":"Right Ventricular Dysfunction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension","volume":"6","author":"Tedford","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic Predictors of Survival in Scleroderma-Related Pulmonary Arterial Hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1053\/gast.2002.33419","article-title":"Endoscopic Screening for Varices in Cirrhosis: Findings, Implications, and Outcomes","volume":"122","author":"Jensen","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.1840160607","article-title":"Prevalence, Classification and Natural History of Gastric Varices: A Long-term Follow-up Study in 568 Portal Hypertension Patients","volume":"16","author":"Sarin","year":"1992","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00420-8","article-title":"Incidence and Natural History of Small Esophageal Varices in Cirrhotic Patients","volume":"38","author":"Merli","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/liv.15181","article-title":"Update on the Management of Gastric Varices","volume":"42","author":"Luo","year":"2022","journal-title":"Liver Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-021-01493-2","article-title":"Pathophysiology and Management of Variceal Bleeding","volume":"81","author":"Alqahtani","year":"2021","journal-title":"Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0168-8278(90)90045-S","article-title":"Spontaneous Regression of Oesophageal Varices after Long-Term Conservative Treatment","volume":"10","author":"Mting","year":"1990","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic Value of Hepatic Venous Pressure Gradient Measurements in Alcoholic Cirrhosis: A 10-Year Prospective Study","volume":"111","author":"Vorobioff","year":"1996","journal-title":"Gastroenterology-Orlando"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2015.06.006","article-title":"The Long-Term Benefits of Nucleos(t)Ide Analogs in Compensated HBV Cirrhotic Patients with No or Small Esophageal Varices: A 12-Year Prospective Cohort Study","volume":"63","author":"Lampertico","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/gastro\/gow018","article-title":"Oesophageal and Gastric Varices: Historical Aspects, Classification and Grading: Everything in One Place","volume":"4","author":"Philips","year":"2016","journal-title":"Gastroenterol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0016-5085(87)90453-7","article-title":"Normal Venous Circulation of the Gastroesophageal Junction A Route to Understanding Varices","volume":"93","author":"Vtanna","year":"1987","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","article-title":"UK Guidelines on the Management of Variceal Haemorrhage in Cirrhotic Patients","volume":"64","author":"Tripathi","year":"2015","journal-title":"Gut"},{"key":"ref_94","first-page":"459","article-title":"Variceal Bleeding: Surgery and Radiology","volume":"32","author":"Jensen","year":"2022","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.dld.2013.12.010","article-title":"Acute Variceal Haemorrhage in the United Kingdom: Patient Characteristics, Management and Outcomes in a Nationwide Audit","volume":"46","author":"Jairath","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(07)61404-4","article-title":"Use of Evidence in WHO Recommendations","volume":"370","author":"Quigley","year":"2007","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of Decompensation and Organ Failure in Cirrhosis: From Peripheral Arterial Vasodilation to Systemic Inflammation Hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/00365520902912555","article-title":"Ascites: Pathogenesis and Therapeutic Principles","volume":"44","author":"Henriksen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The Liver (2010). EASL Clinical Practice Guidelines on the Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis. J. Hepatol., 53, 397\u2013417.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1478-3231.2012.02807.x","article-title":"Current Limits and Future Challenges in the Management of Renal Dysfunction in Patients with Cirrhosis: Report from the International Club of Ascites","volume":"33","author":"Angeli","year":"2013","journal-title":"Liver Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.amjmed.2006.05.007","article-title":"Water and Sodium Retention in Edematous Disorders: Role of Vasopressin and Aldosterone","volume":"119","author":"Schrier","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2036.16.s5.3.x","article-title":"Review Article: Volume Expansion in Patients with Cirrhosis","volume":"16","author":"Henriksen","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jhep.2010.07.002","article-title":"Renal Sodium Retention in Pre-Ascitic Cirrhosis: The More We Know about the Puzzle, the More It Becomes Intricate","volume":"53","author":"Bernardi","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Bosch, J., and Iwakiri, Y. (2018). The Portal Hypertension Syndrome: Etiology, Classification, Relevance, and Animal Models. Hepatol. Int., 12.","DOI":"10.1007\/s12072-017-9827-9"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/00365521.2020.1744709","article-title":"Pathophysiological-Based Treatments of Complications of Cirrhosis","volume":"55","author":"Kimer","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular Pathobiology in Chronic Liver Disease and Cirrhosis\u2014Current Status and Future Directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute Kidney Injury in Cirrhosis","volume":"48","author":"Parikh","year":"2008","journal-title":"Hepatology"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Mehta, R.L., Kellum, J.A., Shah, S.V., Molitoris, B.A., Ronco, C., Warnock, D.G., Levin, A., Bagga, A., Bakkaloglu, A., and Bonventre, J.V. (2007). Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury. Crit. Care, 11.","DOI":"10.1186\/cc5713"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/liv.12549","article-title":"Kidney Injury in Cirrhosis: Pathophysiological and Therapeutic Aspects of Hepatorenal Syndromes","volume":"34","author":"Moller","year":"2014","journal-title":"Liver Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: A Step beyond the International Club of Ascites (ICA) Consensus Document","volume":"71","author":"Angeli","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/ndt\/gfs067","article-title":"Renal Failure in Cirrhosis: Prerenal Azotemia, Hepatorenal Syndrome and Acute Tubular Necrosis","volume":"27","author":"Schrier","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal Failure in Cirrhosis","volume":"361","author":"Schrier","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12072-017-9833-y","article-title":"Pharmacologic Prevention of Variceal Bleeding and Rebleeding","volume":"12","author":"Baiges","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.1840070306","article-title":"Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Prospective Study of Factors Associated with Rebleeding","volume":"7","author":"Poynard","year":"1987","journal-title":"Hepatology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM198710013171403","article-title":"Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices","volume":"317","author":"Pascal","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJM199105303242202","article-title":"Beta-Adrenergic\u2013Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices: An Analysis of Data and Prognostic Factors in 589 Patients from Four Randomized Clinical Trials","volume":"324","author":"Poynard","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.1840080103","article-title":"Nadolol Can Prevent the First Gastrointestinal Bleeding in Cirrhotics: A Prospective, Randomized Study","volume":"8","author":"Bellati","year":"1988","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/0003-4819-117-1-59","article-title":"Prevention of First Bleeding in Cirrhosis: A Meta-Analysis of Randomized Trials of Nonsurgical Treatment","volume":"117","author":"Pagliaro","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1172\/JCI115062","article-title":"Propranolol Ameliorates the Development of Portal-Systemic Shunting in a Chronic Murine Schistosomiasis Model of Portal Hypertension","volume":"87","author":"Sarin","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_120","first-page":"421","article-title":"Renin-Angiotensin-Aldosterone Inhibitors in the Reduction of Portal Pressure: A Systematic Review and Meta-Analysis","volume":"51","author":"Tandon","year":"2010","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious Effects of Beta-Blockers on Survival in Patients with Cirrhosis and Refractory Ascites","volume":"52","author":"Melot","year":"2010","journal-title":"Hepatology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.29267","article-title":"Stratifying Risk in the Prevention of Recurrent Variceal Hemorrhage: Results of an Individual Patient Meta-analysis","volume":"66","author":"Albillos","year":"2017","journal-title":"Hepatology"},{"key":"ref_125","unstructured":"De Franchis, R., Abraldes, J.G., Bajaj, J., Berzigotti, A., Bosch, J., Burroughs, A.K., D\u2019Amico, G., Dell\u2019Era, A., Garcia-Pag\u00e0n, J.C., and Garcia-Tsao, G. (2015). Expanding Consensus in Portal Hypertension Report of the Baveno VI Consensus Workshop: Stratifying Risk and Individualizing Care for Portal Hypertension. J. Hepatol., 743\u2013752."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"65","author":"Abraldes","year":"2017","journal-title":"Hepatology"},{"key":"ref_127","first-page":"332","article-title":"The Treatment of Portal Hypertension: A Meta-Analytic Review","volume":"22","author":"Pagliaro","year":"1995","journal-title":"Hepatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0016-5085(01)81028-3","article-title":"Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive \u03b2-Blockers","volume":"121","author":"Villanueva","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","article-title":"The Changing Role of Beta-Blocker Therapy in Patients with Cirrhosis","volume":"60","author":"Ge","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1665-2681(19)32023-X","article-title":"Beta Blockers in Portal Hypertension. Are They Really a Good Option?","volume":"5","author":"Uribe","year":"2006","journal-title":"Ann. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/ajg.2009.191","article-title":"Management and Treatment of Patients with Cirrhosis and Portal Hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program","volume":"104","author":"Lim","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11901-023-00600-z","article-title":"Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications","volume":"22","author":"Elfeki","year":"2023","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cld.1182","article-title":"Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?","volume":"19","author":"Rabiee","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00281-020-00829-6","article-title":"Adrenergic Regulation of Immune Cell Function and Inflammation","volume":"42","author":"Sharma","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_135","first-page":"1605","article-title":"Carvedilol Improves Liver Cirrhosis in Rats by Inhibiting Hepatic Stellate Cell Activation, Proliferation, Invasion and Collagen Synthesis","volume":"20","author":"Ling","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/liv.12360","article-title":"Beta-Blockers in Portal Hypertension: New Developments and Controversies","volume":"34","author":"Tripathi","year":"2014","journal-title":"Liver Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.gtc.2010.08.015","article-title":"Clinical Pharmacology of Portal Hypertension","volume":"39","year":"2010","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta Adrenergic Blockade and Decompensated Cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for Primary Prophylaxis of Variceal Bleeding in Cirrhotic Patients with Haemodynamic Non-Response to Propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained Virologic Response to Interferon-Free Therapies Ameliorates HCV-Induced Portal Hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.510280507","article-title":"Octreotide Compared With Placebo in A Treatment Strategy for Early Rebleeding in Cirrhosis. A Double Blind, Randomized Pragmatic Trial","volume":"28","author":"Politi","year":"1998","journal-title":"Hepatology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2000-99","article-title":"Variceal Bleeding and Portal Hypertension","volume":"32","author":"Binmoeller","year":"2000","journal-title":"Endoscopy"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1503\/cmaj.051700","article-title":"Current Management of the Complications of Portal Hypertension: Variceal Bleeding and Ascites","volume":"174","author":"Dib","year":"2006","journal-title":"Can. Med. Assoc. J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0168-8278(96)80271-6","article-title":"Effect of Terlipressin on in Vitro Vascular Hyporeactivity of Portal Hypertensive Rats","volume":"24","author":"Staube","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1007\/BF02088736","article-title":"Hemodynamic and Metabolic Effects of Terlipressin in Patients with Cirrhosis Receiving a Nonselective \u03b2-blocker","volume":"41","author":"Vachiery","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2005.41381.x","article-title":"Acute Hemodynamic Effects of Octreotide and Terlipressin in Patients with Cirrhosis: A Randomized Comparison","volume":"100","author":"Baik","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1177\/030006051204000512","article-title":"Terlipressin Resolves Ascites of Cirrhotic Rats through Downregulation of Aquaporin 2","volume":"40","author":"Huang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.50.1.90","article-title":"Comparison of the Effect of Terlipressin and Albumin on Arterial Blood Volume in Patients with Cirrhosis and Tense Ascites Treated by Paracentesis: A Randomised Pilot Study","volume":"50","author":"Moreau","year":"2002","journal-title":"Gut"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Allegretti, A.S., Israelsen, M., Krag, A., Jovani, M., Goldin, A.H., Schulman, A.R., Winter, R.W., and Gluud, L.L. (2017). Terlipressin versus Placebo or No Intervention for People with Cirrhosis and Hepatorenal Syndrome. Cochrane Database Syst. Rev., 2017.","DOI":"10.1002\/14651858.CD005162.pub4"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0253-7613.106436","article-title":"Survival Benefits of Terlipressin and Non-Responder State in Hepatorenal Syndrome: A Meta-Analysis","volume":"45","author":"Hiremath","year":"2013","journal-title":"Indian J. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/liv.14703","article-title":"Terlipressin Has Stood the Test of Time: Clinical Overview in 2020 and Future Perspectives","volume":"40","author":"Kulkarni","year":"2020","journal-title":"Liver Int."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin Therapy for Reversal of Type 1 Hepatorenal Syndrome: A Meta-Analysis of Randomized Controlled Trials","volume":"25","author":"Sagi","year":"2010","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-Generation \u03b2-Blockers Stimulate Nitric Oxide Release from Endothelial Cells through ATP Efflux: A Novel Mechanism for Antihypertensive Action","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Khouri, C., Jouve, T., Blaise, S., Carpentier, P., Cracowski, J.L., and Roustit, M. (2016). Peripheral Vasoconstriction Induced by \u03b2-Adrenoceptor Blockers: A Systematic Review and a Network Meta-Analysis. Br. J. Clin. Pharmacol., 549\u2013560.","DOI":"10.1111\/bcp.12980"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21037\/amj.2017.06.04","article-title":"Is Carvedilol Better than Propranolol in Portal Hypertension?","volume":"2","author":"Wong","year":"2017","journal-title":"AME Med. J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14740338.2020.1734558","article-title":"Development of Hyponatremia after Terlipressin in Cirrhotic Patients with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Observational Study","volume":"19","author":"Xu","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-Blockers: Their New Life from Hypertension to Cancer and Migraine","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/j.1875-9114.1997.tb03097.x","article-title":"Impact of CYP2D6 Poor Metabolizer Phenotype on Propranolol Pharmacokinetics and Response","volume":"17","author":"Sowinski","year":"1997","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Fischer, J., and Ganellin, C.R. (2010). Analogue-Based Drug Discovery II, Wiley-VCH.","DOI":"10.1002\/9783527630035"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5497\/wjp.v5.i1.15","article-title":"Non-Selective Beta-Blockers in Cirrhosis: Current Concepts and Controversies","volume":"5","author":"Rajoriya","year":"2016","journal-title":"World J. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e20191035","DOI":"10.1542\/peds.2019-1035","article-title":"Death Associated With Nadolol for Infantile Hemangioma: A Case for Improving Safety","volume":"145","author":"McGillis","year":"2020","journal-title":"Pediatrics"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1756283X14564673","article-title":"Treatment and Management of Ascites and Hepatorenal Syndrome: An Update","volume":"8","author":"Lenz","year":"2015","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jgh.14009","article-title":"Terlipressin: Current and Emerging Indications in Chronic Liver Disease","volume":"33","author":"Papaluca","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000528","article-title":"Peptide-Based Therapy in Portal Hypertension","volume":"27","author":"Mohanty","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and Somatostatin Analogues: Pharmacokinetics and Pharmacodynamic Effects","volume":"35","author":"Harris","year":"1994","journal-title":"Gut"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/19336950.2022.2055521","article-title":"Mechanism of Carvedilol Induced Action Potential and Calcium Alternans","volume":"16","author":"Kanaporis","year":"2022","journal-title":"Channels"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"H1245","DOI":"10.1152\/ajpheart.00650.2019","article-title":"Effect of Carvedilol on Atrial Excitation-Contraction Coupling, Ca2+ Release, and Arrhythmogenicity","volume":"318","author":"Blatter","year":"2020","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the New Non-selective Beta-blocker of Choice in Patients with Cirrhosis and Portal Hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"327","DOI":"10.51821\/84.2.327","article-title":"Portal Vein Thrombosis: An Overview of Current Treatment Options","volume":"84","author":"Galante","year":"2021","journal-title":"Acta Gastro-Enterol. Belg."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0025-7125(16)30646-0","article-title":"Portal Hypertension","volume":"73","author":"Bosch","year":"1989","journal-title":"Med. Clin. N. Am."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2016.08.033","article-title":"Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients with Cirrhosis","volume":"151","author":"Sarin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and Efficacy of Anticoagulation Therapy with Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients with Liver Cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-Analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"141","DOI":"10.14740\/gr806w","article-title":"Efficacy and Safety of Direct-Acting Oral Anticoagulants Use in Acute Portal Vein Thrombosis Unrelated to Cirrhosis","volume":"10","author":"Nery","year":"2017","journal-title":"Gastroenterol. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for Extended Treatment of Venous Thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct Oral Anticoagulant (DOAC) versus Low-Molecular-Weight Heparin (LMWH) for Treatment of Cancer Associated Thrombosis (CAT): A Systematic Review and Meta-Analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The Efficacy and Safety of Direct Oral Anticoagulants in Noncirrhotic Portal Vein Thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/lt.24708","article-title":"Reversal of Direct Oral Anticoagulants for Liver Transplantation in Cirrhosis: A Step Forward","volume":"23","author":"Intagliata","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The Efficacy and Safety of Direct Oral Anticoagulants vs Traditional Anticoagulants in Cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic Treatment with Direct-Acting Oral Anticoagulants in Patients with Splanchnic Vein Thrombosis and Cirrhosis","volume":"37","author":"Trebicka","year":"2017","journal-title":"Liver Int."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and Safety of Edoxaban for Treatment of Portal Vein Thrombosis Following Danaparoid Sodium in Patients with Liver Cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and Cons of New Oral Anticoagulants","volume":"2013","author":"Bauer","year":"2013","journal-title":"Hematology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/17474086.2016.1112733","article-title":"How to Effectively Manage the Event of Bleeding Complications When Using Anticoagulants","volume":"9","author":"Sartori","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1055\/s-0040-1722192","article-title":"Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis","volume":"121","author":"Valeriani","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of Hepatic Fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of Hepatic Stellate Cell Activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","article-title":"Effects of the FXR Agonist Obeticholic Acid on Hepatic Venous Pressure Gradient (HVPG) in Alcoholic Cirrhosis: A Proof of Concept Phase 2A Study","volume":"60","author":"Mookerjee","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/gut.2005.077453","article-title":"Endothelin-1 Contributes to Maintenance of Systemic but Not Portal Haemodynamics in Patients with Early Cirrhosis: A Randomised Controlled Trial","volume":"55","author":"Tripathi","year":"2006","journal-title":"Gut"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/S0168-8278(16)00258-0","article-title":"Selective Endothelin-A Blockade Decreases Portal Pressure in Patients with Cirrhosis. A Pilot Study Combining a Local Intraarterial and Systemic Administration","volume":"64","author":"Zipprichi","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/apt.14377","article-title":"Randomised Clinical Study: The Effects of Oral Taurine 6g\/Day vs Placebo on Portal Hypertension","volume":"47","author":"Schwarzer","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2003.07497.x","article-title":"Portal Pressure Response to Losartan Compared with Propranolol in Patients with Cirrhosis","volume":"98","author":"De","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2007.01.017","article-title":"AT1 Receptor Antagonist Candesartan in Selected Cirrhotic Patients: Effect on Portal Pressure and Liver Fibrosis Markers","volume":"46","author":"Martini","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized Comparison of Long-Term Carvedilol and Propranolol Administration in the Treatment of Portal Hypertension in Cirrhosis","volume":"36","author":"Moitinho","year":"2002","journal-title":"Hepatology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1872-034X.2007.00165.x","article-title":"New Angiotensin II Type 1 Receptor Blocker Olmesartan Improves Portal Hypertension in Patients with Cirrhosis","volume":"37","author":"Hidaka","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1572-0241.2007.01759.x","article-title":"Irbesartan plus Low-Dose Propranolol versus Low-Dose Propranolol Alone in Cirrhosis: A Placebo-Controlled, Double-Blind Study","volume":"103","author":"Schepke","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1665-2681(19)32156-8","article-title":"A Randomized Study of Losartan vs Propranolol: Effects on Hepatic and Systemic Hemodynamics in Cirrhotic Patients","volume":"2","author":"Viudez","year":"2003","journal-title":"Ann. Hepatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Garcia-Tsao, G., Fuchs, M., Shiffman, M., Borg, B.B., Pyrsopoulos, N., Shetty, K., Gallegos-Orozco, J.F., Reddy, K.R., Feyssa, E., and Chan, J.L. (2019). Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology, 69.","DOI":"10.1002\/hep.30199"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.acthis.2007.08.001","article-title":"Immunolocalization of Farnesoid X Receptor (FXR) in Mouse Tissues Using Tissue Microarray","volume":"110","author":"Higashiyama","year":"2008","journal-title":"Acta Histochem."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.28836","article-title":"Liver Capsule: FXR Agonists against Liver Disease","volume":"64","author":"Fuchs","year":"2016","journal-title":"Hepatology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000445268","article-title":"Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease","volume":"34","author":"Halilbasic","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual Farnesoid X Receptor\/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2\u2212\/\u2212 (Abcb4\u2212\/\u2212) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-17-0557","article-title":"INT-767 Prevents NASH and Promotes Visceral Fat Brown Adipogenesis and Mitochondrial Function","volume":"238","author":"Comeglio","year":"2018","journal-title":"J. Endocrinol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects against Liver Fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid x Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet","volume":"328","author":"Kong","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., and Halilbasic, E. (2012). Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice against Cholestasis. Gastroenterology, 142.","DOI":"10.1053\/j.gastro.2011.10.028"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2014.08.024","article-title":"Hepatic Dimethylarginine-Dimethylaminohydrolase1 Is Reduced in Cirrhosis and Is a Target for Therapy in Portal Hypertension","volume":"62","author":"Mookerjee","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., and Mazzone, M. (2016). FXR Agonist Obeticholic Acid Reduces Hepatic Inflammation and Fibrosis in a Rat Model of Toxic Cirrhosis. Sci. Rep., 6.","DOI":"10.1038\/srep33453"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.3748\/wjg.v20.i37.13493","article-title":"Recent Insights into Farnesoid X Receptor in Non-Alcoholic Fatty Liver Disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/febs.13956","article-title":"Dihydroartemisinin Counteracts Fibrotic Portal Hypertension via Farnesoid X Receptor-Dependent Inhibition of Hepatic Stellate Cell Contraction","volume":"284","author":"Xu","year":"2017","journal-title":"FEBS J."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/hep.25905","article-title":"Promotion of Liver Regeneration\/Repair by Farnesoid X Receptor in Both Liver and Intestine in Mice","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X Receptor Agonist WAY-362450 Attenuates Liver Inflammation and Fibrosis in Murine Model of Non-Alcoholic Steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1098\/rstb.1985.0169","article-title":"Carbon Tetrachloride Toxicity as a Model for Studying Free-Radical Mediated Liver Injury","volume":"311","author":"Slater","year":"1985","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0039-1693115","article-title":"Vascular Targets for the Treatment of Portal Hypertension","volume":"39","author":"Brusilovskaya","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.RES.0000200400.55539.85","article-title":"Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells","volume":"98","author":"He","year":"2006","journal-title":"Circ. Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR Agonist PX20606 Ameliorates Portal Hypertension by Targeting Vascular Remodelling and Sinusoidal Dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X Receptor Antagonizes Nuclear Factor \u03baB in Hepatic Inflammatory Response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1432-0436.2007.00260.x","article-title":"Hepatic Stellate Cells Display a Functional Vascular Smooth Muscle Cell Phenotype in a Three-Dimensional Co-Culture Model with Endothelial Cells","volume":"76","author":"Wirz","year":"2008","journal-title":"Differentiation"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00424-012-1209-5","article-title":"Hepatic Stellate Cells\u2014The Pericytes in the Liver","volume":"465","author":"Hellerbrand","year":"2013","journal-title":"Pflugers Arch."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Schwabl, P., Hambruch, E., Budas, G.R., Supper, P., Burnet, M., Liles, J.T., Birkel, M., Brusilovskaya, K., K\u00f6nigshofer, P., and Peck-Radosavljevic, M. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010060"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1016\/S0168-8278(17)31237-0","article-title":"EDP-305, a Novel and Highly Potent Farnesoid X Receptor Agonist, Improves Liver Steatosis, Ballooning and Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) in a Diet-Induced Murine Model of Non-Alcoholic Steatohepatitis","volume":"66","author":"Jiang","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhep.2005.01.033","article-title":"Taurine Inhibits Oxidative Damage and Prevents Fibrosis in Carbon Tetrachloride-Induced Hepatic Fibrosis","volume":"43","author":"Miyazaki","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/CS20080647","article-title":"Angiotensin-(1-7), an Alternative Metabolite of the Renin-Angiotensin System, Is up-Regulated in Human Liver Disease and Has Antifibrotic Activity in the Bile-Duct-Ligated Rat","volume":"117","author":"Lubel","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Klein, S., Herath, C.B., Schierwagen, R., Grace, J., Haltenhof, T., Uschner, F.E., Strassburg, C.P., Sauerbruch, T., Walther, T., and Angus, P.W. (2015). Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138732"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11901-019-00448-2","article-title":"Future Pharmacological Therapies of Portal Hypertension","volume":"18","author":"Ortiz","year":"2019","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Grace, J.A., Klein, S., Herath, C.B., Granzow, M., Schierwagen, R., Masing, N., Walther, T., Sauerbruch, T., Burrell, L.M., and Angus, P.W. (2013). Activation of the Mas Receptor by Angiotensin-(1-7) in the Renin-Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis. Gastroenterology, 145.","DOI":"10.1053\/j.gastro.2013.06.036"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II Induces Contraction and Proliferation of Human Hepatic Stellate Cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/gast.2001.26288","article-title":"Liver, Pancreas, and Biliary Tract: Randomized Comparison of Long-Term Losartan versus Propranolol in Lowering Portal Pressure in Cirrhosis","volume":"121","author":"Albillos","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril Reduces Portal Pressure Effectively in Portal Hypertensive Patients with Low Portal Venous Velocity","volume":"38","author":"Baik","year":"2003","journal-title":"J. Gastroenterol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3350\/cmh.2014.20.4.376","article-title":"Effects of Candesartan and Propranolol Combination Therapy versus Propranolol Monotherapy in Reducing Portal Hypertension","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/liv.14757","article-title":"Effect of ET-A Blockade on Portal Pressure and Hepatic Arterial Perfusion in Patients with Cirrhosis: A Proof of Concept Study","volume":"41","author":"Zipprich","year":"2021","journal-title":"Liver Int."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Gracia-Sancho, J., Manicardi, N., Ortega-Ribera, M., Maeso-D\u00edaz, R., Guix\u00e9-Muntet, S., Fern\u00e1ndez-Iglesias, A., Hide, D., Garc\u00eda-Calder\u00f3, H., Boyer-D\u00edaz, Z., and Contreras, P.C. (2019). Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol. Commun., 3.","DOI":"10.1002\/hep4.1360"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised Clinical Trial: Emricasan versus Placebo Significantly Decreases ALT and Caspase 3\/7 Activation in Subjects with Non-Alcoholic Fatty Liver Disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(85)80770-4","article-title":"Reduction of the Increased Portal Vascular Resistance of the Isolated Perfused Cirrhotic Rat Liver by Vasodilators","volume":"1","author":"Bhathal","year":"1985","journal-title":"J. Hepatol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.510280405","article-title":"Endothelial Dysfunction and Decreased Production of Nitric Oxide in the Intrahepatic Microcirculation of Cirrhotic Rats","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0016-5085(99)70408-7","article-title":"Impaired Endothelial Nitric Oxide Synthase Activity Associated with Enhanced Caveolin Binding in Experimental Cirrhosis in the Rat","volume":"117","author":"Shah","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1161\/01.STR.0000143319.73503.38","article-title":"Effects of Statins on Endothelium and Signaling Mechanisms","volume":"35","author":"Endres","year":"2004","journal-title":"Stroke"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/liv.12606","article-title":"Integrin-Linked Kinase Regulates Endothelial Cell Nitric Oxide Synthase Expression in Hepatic Sinusoidal Endothelial Cells","volume":"35","author":"Shafiei","year":"2015","journal-title":"Liver Int."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.44.5.749","article-title":"Hepatic and Splanchnic Nitric Oxide Activity in Patients with Cirrhosis","volume":"44","author":"Sarela","year":"1999","journal-title":"Gut"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin Attenuates Hepatic Fibrosis in Rats after Bile Duct Ligation via Decreased Turnover of Hepatic Stellate Cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 Exerts Antifibrotic and Vasoprotective Effects in Cirrhotic Rat Livers: Behind the Molecular Mechanisms of Statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Uschner, F.E., Ranabhat, G., Choi, S.S., Granzow, M., Klein, S., Schierwagen, R., Raskopf, E., Gautsch, S., Van Der Ven, P.F.M., and F\u00fcrst, D.O. (2015). Statins Activate the Canonical Hedgehog-Signaling and Aggravate Non-Cirrhotic Portal Hypertension, but Inhibit the Non-Canonical Hedgehog Signaling and Cirrhotic Portal Hypertension. Sci. Rep., 5.","DOI":"10.1038\/srep14573"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin Enhances Hepatic Nitric Oxide Production and Decreases the Hepatic Vascular Tone in Patients with Cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_253","first-page":"485","article-title":"The Use of Statins in Patients With Cirrhosis","volume":"14","author":"Kaplan","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","article-title":"Hypercholesterolemia: The Role of PCSK9","volume":"625\u2013626","author":"Melendez","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical Efficacy and Safety of Achieving Very Low LDL-Cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1074248418769040","article-title":"The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia","volume":"23","author":"White","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.drudis.2022.01.014","article-title":"Development of Small-Molecule PCSK9 Inhibitors for the Treatment of Hypercholesterolemia","volume":"27","author":"Ahamad","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The Role of PCSK9 in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors","volume":"24","author":"Theocharidou","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and Inflammation: Role of Shear Stress, pro-Inflammatory Cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","article-title":"PCSK9 Inhibitors for Treating Hypercholesterolemia","volume":"21","author":"Pasta","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 Inhibitors: A New Lipid-Lowering Therapy","volume":"878","author":"Daum","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.numecd.2021.11.015","article-title":"Synergistic Actions between Angiotensin-Converting Enzyme Inhibitors and Statins in Atherosclerosis","volume":"32","author":"Borghi","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.febslet.2006.02.080","article-title":"Hepatic Guanylate Cyclase Activity Is Decreased in a Model of Cirrhosis: A Quantitative Cytochemistry Study","volume":"580","author":"Davies","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2006.01.032","article-title":"Increased Phosphodiesterase-5 Expression Is Involved in the Decreased Vasodilator Response to Nitric Oxide in Cirrhotic Rat Livers","volume":"44","author":"Iwakiri","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Nitric Oxide and Cyclic GMP in Cell Signaling and Drug Development","volume":"355","author":"Murad","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20090601","article-title":"Administration of a Low Dose of Sildenafil for 1 Week Decreases Intrahepatic Resistance in Rats with Biliary Cirrhosis: The Role of NO Bioavailability","volume":"119","author":"Lee","year":"2010","journal-title":"Clin. Sci."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The Phosphodiesterase-5-Inhibitor Udenafil Lowers Portal Pressure in Compensated Preascitic Liver Cirrhosis. A Dose-Finding Phase-II-Study","volume":"47","author":"Kreisel","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3748\/wjg.v16.i39.5009","article-title":"Haemodynamic and Renal Effects of Tadalafil in Patients with Cirrhosis","volume":"16","author":"Kalambokis","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_270","first-page":"1616","article-title":"Thalidomide Inhibits Tumor Necrosis Factor \u03b1, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal-Hypertensive Rats","volume":"23","author":"Cadelina","year":"1996","journal-title":"Hepatology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1478-3231.2009.01983.x","article-title":"Inhibition of Hepatic Tumour Necrosis Factor-\u03b1 Attenuates the Anandamide-Induced Vasoconstrictive Response in Cirrhotic Rat Livers","volume":"29","author":"Yang","year":"2009","journal-title":"Liver Int."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2036.2003.01809.x","article-title":"A Pilot Study to Investigate the Use of Oxpentifylline (Pentoxifylline) and Thalidomide in Portal Hypertension Secondary to Alcoholic Cirrhosis","volume":"19","author":"Austin","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12072-017-9806-1","article-title":"Novelties in the Pathophysiology and Management of Portal Hypertension: New Treatments on the Horizon","volume":"12","author":"Kang","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11901-023-00598-4","article-title":"Emerging Therapeutic Targets for Portal Hypertension","volume":"22","author":"Felli","year":"2023","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Formenti, S.C., Hawtin, R.E., Dixit, N., Evensen, E., Lee, P., Goldberg, J.D., Li, X., Vanpouille-Box, C., Schaue, D., and McBride, W.H. (2019). Baseline T Cell Dysfunction by Single Cell Network Profiling in Metastatic Breast Cancer Patients. J. Immunother. Cancer, 7.","DOI":"10.1186\/s40425-019-0633-x"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.13177","article-title":"Simtuzumab Treatment of Advanced Liver Fibrosis in HIV and HCV-Infected Adults: Results of a 6-Month Open-Label Safety Trial","volume":"36","author":"Meissner","year":"2016","journal-title":"Liver Int."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2018.03.018","article-title":"Beneficial Effects of the Peroxisome Proliferator-Activated Receptor \u03b1\/\u03b3 Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension","volume":"188","author":"Tsai","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from Liver Fibrosis by a Peroxisome Proliferator-Activated Receptor \u03b4 Agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 Activation Improves Endothelial Dysfunction and Reduces Fibrosis and Portal Pressure in Cirrhotic Rats","volume":"56","author":"Russo","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha\/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 Agonist Saroglitazar Improves Liver Histopathology and Biochemistry in Experimental NASH Models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.biopha.2018.12.130","article-title":"Biochemical and Histological Characterisation of an Experimental Rodent Model of Non-Alcoholic Steatohepatitis\u2014Effects of a Peroxisome Proliferator-Activated Receptor Gamma (PPAR-\u03b3) Agonist and a Glucagon-like Peptide-1 Analogue","volume":"111","author":"Daniels","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Portal Hypertension and Hepatic Fibrosis in Experimental Advanced Chronic Liver Disease","volume":"74","author":"Robert","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/hep.22166","article-title":"Increased Oxidative Stress in Cirrhotic Rat Livers: A Potential Mechanism Contributing to Reduced Nitric Oxide Bioavailability","volume":"47","author":"Bosch","year":"2008","journal-title":"Hepatology"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jhep.2012.09.010","article-title":"Recombinant Human Manganese Superoxide Dismutase Reduces Liver Fibrosis and Portal Pressure in CCl 4-Cirrhotic Rats","volume":"58","author":"Guillaume","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Burtenshaw, D., Hakimjavadi, R., Redmond, E.M., and Cahill, P.A. (2017). Nox, Reactive Oxygen Species and Regulation of Vascular Cell Fate. Antioxidants, 6.","DOI":"10.3390\/antiox6040090"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clinre.2018.10.004","article-title":"NADPH Oxidase 1\/4 Inhibition Attenuates the Portal Hypertensive Syndrome via Modulation of Mesenteric Angiogenesis and Arterial Hyporeactivity in Rats","volume":"43","author":"Deng","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol Improves Intrahepatic Endothelial Dysfunction and Reduces Hepatic Fibrosis and Portal Pressure in Cirrhotic Rats","volume":"58","author":"Rosado","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide Adenine Dinucleotide Phosphate Oxidase in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in Liver Disease","volume":"50","author":"Semela","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cld.2019.07.007","article-title":"Portal Hypertension: Pathogenesis and Diagnosis","volume":"23","author":"Turco","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1152\/ajpgi.00252.2011","article-title":"Effects of the Combined Administration of Propranolol plus Sorafenib on Portal Hypertension in Cirrhotic Rats","volume":"302","author":"Abraldes","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2013.02.026","article-title":"Study of the Cellular Mechanism of Sunitinib Mediated Inactivation of Activated Hepatic Stellate Cells and Its Implications in Angiogenesis","volume":"705","author":"Majumder","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"36220","DOI":"10.18632\/oncotarget.26333","article-title":"The Multikinase Inhibitor Regorafenib Decreases Angiogenesis and Improves Portal Hypertension","volume":"9","author":"Uschner","year":"2018","journal-title":"Oncotarget"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jgh.12480","article-title":"Beneficial Effects of Dual Vascular Endothelial Growth Factor Receptor\/Fibroblast Growth Factor Receptor Inhibitor Brivanib Alaninate in Cirrhotic Portal Hypertensive Rats","volume":"29","author":"Lin","year":"2014","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrgastro.2014.10","article-title":"HCC Therapies\u2014Lessons Learned","volume":"11","author":"Galle","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ptr.2362","article-title":"Review of Pharmacological Effects of Glycyrrhiza Sp. and Its Bioactive Compounds","volume":"22","author":"Asl","year":"2008","journal-title":"Phytother. Res."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"10947","DOI":"10.1038\/s41598-017-11468-7","article-title":"Voluntary Liquorice Ingestion Increases Blood Pressure via Increased Volume Load, Elevated Peripheral Arterial Resistance, and Decreased Aortic Compliance","volume":"7","author":"Hautaniemi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1074\/jbc.M411673200","article-title":"Licorice Compounds Glycyrrhizin and 18\u03b2-Glycyrrhetinic Acid Are Potent Modulators of Bile Acid-Induced Cytotoxicity in Rat Hepatocytes","volume":"280","author":"Gumpricht","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"641597","DOI":"10.1155\/2014\/641597","article-title":"Hepatoprotective Effects of Silybum Marianum (Silymarin) and Glycyrrhiza Glabra (Glycyrrhizin) in Combination: A Possible Synergy","volume":"2014","author":"Rasool","year":"2014","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0041-0101(98)00263-3","article-title":"The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats","volume":"37","author":"Lin","year":"1999","journal-title":"Toxicon"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00005-012-0183-0","article-title":"The Role of Glycyrrhizin, an Inhibitor of HMGB1 Protein, in Anticancer Therapy","volume":"60","author":"Smolarczyk","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Pun, C.K., Huang, H.C., Chang, C.C., Chuang, C.L., Yen, C.H., Hsu, S.J., Lee, F.Y., Hou, M.C., and Huang, Y.H. (2021). Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147662"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic Microcirculation and Mechanisms of Portal Hypertension","volume":"16","author":"Marrone","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jgh.12360","article-title":"Effects of Fasudil on the Portal and Systemic Hemodynamics of Patients with Cirrhosis","volume":"29","author":"Fukuda","year":"2014","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41598-019-38678-5","article-title":"Rho-Kinase Inhibitor Coupled to Peptide-Modified Albumin Carrier Reduces Portal Pressure and Increases Renal Perfusion in Cirrhotic Rats","volume":"9","author":"Klein","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.21228","article-title":"The eNOS Cofactor Tetrahydrobiopterin Improves Endothelial Dysfunction in Livers of Rats with CCl4 Cirrhosis","volume":"44","author":"Matei","year":"2006","journal-title":"Hepatology"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II Type 1 Receptor-Mediated Janus Kinase 2 Activation Induces Liver Fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gutjnl-2015-309600","article-title":"Janus-Kinase-2 Relates Directly to Portal Hypertension and to Complications in Rodent and Human Cirrhosis","volume":"66","author":"Klein","year":"2015","journal-title":"Gut"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yjmcc.2017.08.003","article-title":"Aicar Treatment Reduces Interstitial Fibrosis in Aging Mice: Suppression of the Inflammatory Fibroblast","volume":"111","author":"Cieslik","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00109-019-01746-4","article-title":"AMPK Agonist AICAR Ameliorates Portal Hypertension and Liver Cirrhosis via NO Pathway in the BDL Rat Model","volume":"97","author":"Hu","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1152\/ajpgi.00010.2015","article-title":"Metformin Reduces Hepatic Resistance and Portal Pressure in Cirrhotic Rats","volume":"309","author":"Tripathi","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1476-511X-13-115","article-title":"Metformin Enhances Nitric Oxide Production and Diminishes Rho Kinase Activity in Rats with Hyperlipidemia","volume":"13","author":"Liu","year":"2014","journal-title":"Lipids Health Dis."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/apt.16460","article-title":"Randomised Clinical Study: Acute Effects of Metformin versus Placebo on Portal Pressure in Patients with Cirrhosis and Portal Hypertension","volume":"54","author":"Rittig","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.21785","article-title":"Reversal of Portal Hypertension and Hyperdynamic Splanchnic Circulation by Combined Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Blockade in Rats","volume":"46","author":"Fernandez","year":"2007","journal-title":"Hepatology"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1152\/ajpgi.00336.2005","article-title":"Mild Increases in Portal Pressure Upregulate Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase in the Intestinal Microcirculatory Bed, Leading to a Hyperdynamic State","volume":"290","author":"Abraldes","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2017.12.027","article-title":"Cardiopulmonary Hemodynamics and C-Reactive Protein as Prognostic Indicators in Compensated and Decompensated Cirrhosis","volume":"68","author":"Turco","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The Hyperdynamic Circulation of Chronic Liver Diseases: From the Patient to the Molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial Translocation (BT) in Cirrhosis","volume":"41","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-139-3-200308050-00008","article-title":"The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis: A Randomized Trial","volume":"139","author":"Rasaratnam","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2018.08.026","article-title":"Effects of Long-Term Norfloxacin Therapy in Patients With Advanced Cirrhosis","volume":"155","author":"Moreau","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_328","unstructured":"US Food and Drug Administration (2023). FDA Approves Treatment to Improve Kidney Function in Adults with Hepatorenal Syndrome, US Food and Drug Administration."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1016\/j.crphar.2023.100163","article-title":"OCE-205 in Rats and Non-Human Primates: Pharmacokinetic and Pharmacodynamic Analysis","volume":"5","author":"Bukofzer","year":"2023","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2125.2007.02921.x","article-title":"Ischaemic Complications of Glypressin in Liver Disease: A Case Series","volume":"64","author":"Donnellan","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/jpp.JPP_23_18","article-title":"Terlipressin-Induced Ischemic Complications: A Systematic Review of Published Case Reports","volume":"9","author":"Sarma","year":"2018","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients with Cirrhosis and Hepatorenal Syndrome Type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a Vasoactive Prodrug Recommended in Hepatorenal Syndrome, Is an Agonist of Human V1, V2 and V1B Receptors: Implications for Its Safety Profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of Terlipressin on the Aquaretic System: Evidence of Antidiuretic Effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/CCM.0000000000004617","article-title":"Fluid Overload and Mortality in Adult Critical Care Patients-A Systematic Review and Meta-Analysis of Observational Studies","volume":"48","author":"Messmer","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJMra032401","article-title":"Acute Renal Failure and Sepsis","volume":"351","author":"Schrier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1053\/j.ajkd.2019.10.010","article-title":"Critical Care Nephrology: Core Curriculum 2020","volume":"75","author":"Griffin","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/jtbi.1996.0130","article-title":"Rational Design of Receptor Partial Agonists and Possible Mechanisms of Receptor Partial Activation: A Theory","volume":"181","author":"Zhu","year":"1996","journal-title":"J. Theor. Biol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4254\/wjh.v11.i5.483","article-title":"Successful Treatment of Noncirrhotic Portal Hypertension with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report","volume":"11","author":"Alexopoulou","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"e0276","DOI":"10.1097\/HC9.0000000000000276","article-title":"Safety and Pharmacokinetics of BI 685509, a Soluble Guanylyl Cyclase Activator, in Patients with Cirrhosis: A Randomized Phase Ib Study","volume":"7","author":"Lawitz","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.gastro.2024.06.007","article-title":"Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension","volume":"167","author":"Zhu","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_344","doi-asserted-by":"crossref","unstructured":"Anghel, S.A., Dinu-Pirvu, C.-E., Costache, M.-A., Voiculescu, A.M., Ghica, M.V., Anu\u021ba, V., and Popa, L. (2024). Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179371"},{"key":"ref_345","doi-asserted-by":"crossref","unstructured":"Qahwaji, R., Ashankyty, I., Sannan, N.S., Hazzazi, M.S., Basabrain, A.A., and Mobashir, M. (2024). Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070940"},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: A Review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","article-title":"Polymorphisms of Human Cytochrome P450 2C9 and the Functional Relevance","volume":"278","author":"Zhou","year":"2010","journal-title":"Toxicology"},{"key":"ref_348","first-page":"191","article-title":"Pharmacogenomics: The Right Drug to the Right Person","volume":"1","author":"Aneesh","year":"2009","journal-title":"J. Clin. Med. Res."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","article-title":"Clinical Relevance of Genetic Polymorphisms in the Human CYP2C9 Gene","volume":"33","author":"Schwarz","year":"2003","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1291\/hypres.31.1549","article-title":"Genetic Variations of CYP2C9 in 724 Japanese Individuals and Their Impact on the Antihypertensive Effects of Losartan","volume":"31","author":"Yin","year":"2008","journal-title":"Hypertens. Res."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals","volume":"10","author":"Ladero","year":"2006","journal-title":"Mol. Diagn. Ther."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lfs.2005.04.049","article-title":"Ethnic Differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) Genotypes in Japanese and Israeli Populations","volume":"78","author":"Nakai","year":"2005","journal-title":"Life Sci."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","article-title":"Allele and Genotype Frequencies of CYP2C9 in a Korean Population","volume":"60","author":"Bae","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_354","doi-asserted-by":"crossref","unstructured":"Chen, K., Xiao, P., Li, G., Wang, C., and Yang, C. (2021). Distributive Characteristics of the CYP2C9 and AGTR1 Genetic Polymorphisms in Han Chinese Hypertensive Patients: A Retrospective Study. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-01895-w"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s40142-013-0017-3","article-title":"Genetics of Population Differences in Drug Response","volume":"1","author":"Bachtiar","year":"2013","journal-title":"Curr. Genet. Med. Rep."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13073-017-0502-5","article-title":"Genetic Variation in Human Drug-Related Genes","volume":"9","author":"Tremmel","year":"2017","journal-title":"Genome Med."},{"key":"ref_357","doi-asserted-by":"crossref","unstructured":"(2008). The SEARCH Collaborative Group. SLCO1B1 Variants and Statin-Induced Myopathy\u2014A Genomewide Study. N. Engl. J. Med., 359, 789\u2013799.","DOI":"10.1056\/NEJMoa0801936"},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"106367","DOI":"10.1016\/j.cct.2021.106367","article-title":"SACRED: Effect of Simvastatin on Hepatic Decompensation and Death in Subjects with High-Risk Compensated Cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation","volume":"104","author":"Kaplan","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FJC.0000000000000119","article-title":"Association of Common Polymorphisms in \u03921-Adrenergic Receptor With Antihypertensive Response to Carvedilol","volume":"64","author":"Si","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"\u03921-Adrenergic Receptor Polymorphisms and Antihypertensive Response to Metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hep.21000","article-title":"Influence of Beta-2 Adrenergic Receptor Gene Polymorphism on the Hemodynamic Response to Propranolol in Patients with Cirrhosis","volume":"43","author":"Turnes","year":"2006","journal-title":"Hepatology"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2146\/ajhp150946","article-title":"Implementation of Inpatient Models of Pharmacogenetics Programs","volume":"73","author":"Cavallari","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/clpt.2013.59","article-title":"The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation","volume":"94","author":"Shuldiner","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium","volume":"101","author":"Cecchin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","article-title":"Pharmacogenomics: Current Status and Future Perspectives","volume":"24","author":"Pirmohamed","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_366","doi-asserted-by":"crossref","unstructured":"Hulsen, T., Jamuar, S.S., Moody, A.R., Karnes, J.H., Varga, O., Hedensted, S., Spreafico, R., Hafler, D.A., and McKinney, E.F. (2019). From Big Data to Precision Medicine. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00034"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256453","article-title":"The AmpliChipTM CYP450 Genotyping Test: Integrating a New Clinical Tool","volume":"10","author":"Susce","year":"2006","journal-title":"Mol. Diagn. Ther."},{"key":"ref_368","doi-asserted-by":"crossref","unstructured":"Hossam Abdelmonem, B., Abdelaal, N.M., Anwer, E.K.E., Rashwan, A.A., Hussein, M.A., Ahmed, Y.F., Khashana, R., Hanna, M.M., and Abdelnaser, A. (2024). Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071467"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41397-020-00196-3","article-title":"Global Distribution of CYP2C19 Risk Phenotypes Affecting Safety and Effectiveness of Medications","volume":"21","author":"Biswas","year":"2021","journal-title":"Pharmacogenomics J."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/2\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:37Z","timestamp":1759919677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/2\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":370,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["metabo15020072"],"URL":"https:\/\/doi.org\/10.3390\/metabo15020072","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}